Juvabis designs next-generation antibacterial therapeutics that withstand mechanisms of bacterial drug-resistance and at the same time display superior tolerability due to increased target selectivity by rational design. Juvabis has been founded around a proprietary technology developed by researchers at the University of Zurich, and a pipeline of early drug candidates discovered in collaboration with researchers at the ETH Zurich and Wayne State University in Detroit.
Company Details
- Address
- Zurich, Zurich 8001, Ch
- in****@****bis.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- juvabis.com
- Keywords
- Milan.
- HQ
- Zurich, Zurich
Juvabis Ag Questions
Juvabis Ag's website is juvabis.com
Juvabis Ag's LinkedIn profile is https://ch.linkedin.com/company/juvabis
Juvabis Ag's industry is
Pharmaceutical Manufacturing
Juvabis Ag's top competitors are
Endogena Therapeutics, Inc.,
Metriopharm,
Molecular Partners,
Linkster Therapeutics,
Novago Therapeutics,
Immunos Therapeutics Ag,
Naicons,
Biothink Pharma,
Araris Biotech Ag,
Athebio Ag.
Juvabis Ag's support email address is info@juvabis.com
Juvabis Ag's categories are Pharmaceutical Manufacturing
